Monitor upcoming data catalysts: Angel Pharma cohort 1 atopic dermatitis topline in March 2027, HS Phase 1b initial data in 1H 2027, and ALPS ASH poster presentation in December 2026. Cash runway into Q2 2028 provides no near-term financing pressure.
Drug in focus
CRVS drug pipeline →soquelitinib
● Neutral Named in this 8-K- Impact
- Phase
- Phase 3 (registrational for PTCL); Phase 2 (atopic dermatitis, ALPS); Phase 1b (hidradenitis suppurativa)
- Time to market
- If the Phase 3 PTCL trial succeeds at its interim futility analysis (Q1 2027) and final readout (estimated primary completion November 2027), a potential NDA submission could occur in 2028, with FDA approval possible in 2029 at the earliest. The atopic dermatitis program is earlier-stage (Phase 2 topline in Q3 2027) and would require additional Phase 3 trials before any regulatory submission.
- Next catalyst
- None dated
What to watchThe next major binary catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months away). A positive result would validate soquelitinib's novel ITK-inhibitor mechanism in oncology and support continued enrollment toward the primary completion in late 2027. A futility stop would severely damage the thesis. Separately, the SIERRA1 atopic dermatitis Phase 2 topline data in Q3 2027 will test the drug's potential in a large immunology market. The ASH 2026 poster (Dec 14) on ALPS data (n=3) is an early readout with limited stock-moving potential.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $10.54entry
- T+1 · 8d ago +7.68%α +5.32% · $11.35
- T+5 · 4d ago +0.95%α −1.65% · $10.64
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Corvus Pharmaceuticals reported Q3 2026 net loss of $20.3M, wider than the $10.2M loss in Q3 2025, driven by higher R&D costs for soquelitinib trials. Cash runway extends into Q2 2028 with $202.9M at quarter end. Key pipeline milestones include ALPS Phase 2 positive initial data, Angel Pharma cohort 1 enrollment complete with topline data expected March 2027, and Phase 1b HS trial enrolling with initial data in 1H 2027.
Key Financial Metrics
Key Facts
- Net loss for Q3 2026 was $20.3M vs $10.2M in Q3 2025
- Cash, cash equivalents and marketable securities of $202.9M at September 30, 2026
- Cash runway expected into Q2 2028
- R&D expenses $17.8M in Q3 2026 vs $8.5M in Q3 2025
- ALPS Phase 2 trial initial data published; all 3 patients had positive response
- Angel Pharma completed enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data March 2027
- Phase 1b hidradenitis suppurativa trial enrolling; initial data 1H 2027
- Phase 2 asthma trial to initiate by Q1 2027
Financial Impact
Net loss widened to $20.3M from $10.2M YoY; cash burn $17.8M R&D spend in quarter
Risk Factors
- Net loss widening significantly YoY with no approved products or revenue
- Clinical-stage biotech with binary data readouts ahead
- Higher R&D spend may accelerate cash burn if trials expand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-007175 |
| Document: f8k_110526.htm | 0001171843-26-007175 |
| Document: 0001171843-26-007175-index-headers.html | 0001171843-26-007175 |
| Document: 0001171843-26-007175-index.html | 0001171843-26-007175 |
| Document: 0001171843-26-007175.txt | 0001171843-26-007175 |
| 8-K Data (Synthetic) | 0001171843-26-007175 |
Track record
15 reports on CRVS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $10.54 Now $10.60 +0.57% settles Feb 4
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
- Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
- Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
- May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers